COA on Every ProductUSP Certified MaterialsProudly Canadian ManufacturerAll Excipients: USP-Grade ◆ Low Endotoxin ◆ Low MetalRaw Materials Sourced from GMP-Manufacturing FacilitiesCOA on Every ProductUSP Certified MaterialsProudly Canadian ManufacturerAll Excipients: USP-Grade ◆ Low Endotoxin ◆ Low MetalRaw Materials Sourced from GMP-Manufacturing Facilities

Tesamorelin 10 mg

Tesamorelin, a stabilized growth-hormone-releasing hormone (GHRH) analog, 10 mg. For research purposes only.

🇨🇦 Canadian First Lyfe is the first manufacturer of dual chamber pens in Canada. Learn More → View Certificate of Analysis Independent third‑party lab report · PDF

Description

Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH), notable in research for its effect on the GH axis and fat metabolism.

Commonly explored in research for:

  • The GH / IGF-1 axis and secretagogue signalling
  • Adipose-tissue metabolism and visceral-fat models
  • Lipid metabolism research
  • Body-composition studies

Supplied as 10 mg lyophilized powder; also available in the Lyfe pen.

⚖️

Chemical Overview

Key identifiers & structural data

🔬 Structural Data

About Tesamorelin

ClassificationGrowth hormone-releasing factor
CAS Registry218949-48-5
Molecular Mass5135.9
Residue Count44
Chain SequenceTyr-D-Ala-Ala-Ala
Molecular FormulaC221H366N72O67S
🔗 View on PubChem
📑

Research Literature

Published studies & clinical data

Journal of Clinical Endocrinology & Metabolism

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients

2009 • PMID: 19846735

Falutz J, Allas S, Blot K, Potvin D, Kotler D

Read Paper ↗
AIDS

Tesamorelin treatment reduces visceral fat and improves metabolic parameters in HIV-infected patients

2010 • PMID: 20588173

Falutz J, Allas S, Blot K, Potvin D, Kotler D

Read Paper ↗
Lancet

Tesamorelin for the treatment of excess abdominal fat in HIV-infected patients

2010 • PMID: 20656467

Falutz J, Allas S, Blot K, Potvin D, Kotler D

Read Paper ↗